CFN Media

February 09, 2017 09:15 ET

GB Sciences Embraces Cannabinoid Complexities, Plus New Interview -- CFN Media

SEATTLE, WA--(Marketwired - Feb 9, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article and interview discussing GB Sciences Inc.'s (OTCQB: GBLX) holistic approach to cannabis biopharmaceutical development, its commitment to laboratory best practices and certifications, as well as the company's recent patent filings. CFN Media talks to CSO Dr. Andrea Small-Howard about all of the above in an exclusive video interview.

The cannabis plant is incredibly complex with over 400 chemical entities, including major compounds like tetrahydrocannabinol (THC) and cannabidiol (CBD) that have opposing effects. While the plant has been cultivated for at least 6,000 years, its pharmacological properties have only been analyzed since the end of the nineteenth century. Many breakthroughs didn't occur until after 2000 when the human endocannabinoid system became more understood. Most companies involved in the cannabis industry are focused on only two of these compounds -- THC and CBD -- and their effects on a limited number of cannabinoid receptors.

GB Sciences is taking a different approach by embracing the complexity of both the cannabis plant and the endocannabinoid system. By taking a holistic approach, the company aims to leverage the natural interactions between dozens of cannabinoids, terpenes and other phytochemicals within the cannabis plant on many different receptors within the endocannabinoid system. These targets are identified using both high-throughput screening of accepted cellular models of human diseases and complex statistical and computer models designed to predict outcomes.

GB Sciences has started to build a patent portfolio around the approach by working with Fenwick & West. In the last few months, the company has filed two patents and licensed another, for indications ranging from Parkinson's and Alzheimer's disease to chronic arthritis and inflammatory bowel syndrome to cardiac hypertrophy.

Please follow the link to read the full article and see the interview:

Learn how to become a CFN Media client company, brand or entrepreneur:

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand:

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone:

About CFN Media

CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.


Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns CFN Media and, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit:

Contact Information